Canvax Biotech
![]() |
||
Canvax is a leading manufacturer and supplier of the most innovative solutions, kits and R&D Reagents inside Molecular Biology fields. Since its foundation in 2001, Canvax offers reliable, cost-effective and easy-to-use innovative tools for research. Based in Córdoba (Spain), since its beginning it has focused on R&D of multiplex high throughput platforms (HTS) for Drug discovery and Diagnostic applied biosensors. Over a decade later, Canvax is a worldwide leading expert in GPCR expression in heterologous cells, with important patents and exclusive know-how. Canvax prides itself to be the first company to get an unprecedented milestone that could revolutionize the Diagnostics sector: Canvax established stable high-level expression of odour GPCRs into heterologous cell lines in 2014. This key milestone, that could be applied in diagnostic, perfume and cosmetic industry, are being employed to obtain a molecular nose, a sensitive and non-invasive diagnostic molecular device for early detection of cancer, as the nose of trained dogs do. Thanks to this project, Canvax was awarded, in 2013, with the largest Public & Private Contract for Pre competitive Technology Development in Spanish history. Website : www.lifescience.canvaxbiotech.com |
![COVID-19](https://www.clinisciences.com/en/upload/thumbs/covid-19-research-hccexw-d20f23.jpg)
COVID-19
A new coronavirus (Covid-19 / 2019-nCoV) close to the Severe Acute Respiratory Syndrome (SARS) virus and the Middle East Respiratory Syndrome Virus (MERS) was discovered in early January in the city of Wuhan, China.
The symptoms of this new coronavirus infection are similar to those of seasonal flu, SARS or MERS. Transmission and incubation time also appear to be similar to other coronaviruses. Coronavirus Covid-19 (2019-nCoV) appears to be slightly more contagious than seasonal influenza virus and its infection is slightly more severefor susceptible individuals.
For much of their known history, the coronaviruses were regarded as relatively benign pathogens with little potential to cause human harm. However, the emergence of SARS and MERS in recent decades has brought coronaviruses into the global spotlight and they are now included on the World Health Organization's List of Blueprint Priority Diseases. To support ongoing research and development, we offers a complete range of products for this family of viruses.